![](\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2025\/07\/dec64c7259690719f478a0771791c1f7fd7a63b6-4500x3000.jpg\"\/)
<\/p>\n<\/p>\n
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may be more effective than metformin for reducing the risk of dementia<\/a> in patients with type 2 diabetes<\/a>, according to findings from a recent study.1<\/p>\n Leveraging a decade of data from the TriNetX database for adults with type 2 diabetes who initiated either GLP-1 RAs or metformin as first-line therapy, the study found GLP-1 RAs significantly reduced the risk of overall dementia\u2014particularly Alzheimer\u2019s disease and non-vascular dementias\u2014compared with metformin. Notably, GLP-1 RAs also provided substantial reductions in all-cause mortality, further supporting the early use of GLP-1 RAs in patients with type 2 diabetes at risk of cognitive decline.1<\/p>\n Previous research has indicated a heightened risk of developing dementia among individuals with type 2 diabetes, with dementia risk increasing the longer a person has diabetes and the more severe it is.2 While both GLP-1 RAs and metformin have both demonstrated potential neuroprotective effects in type 2 diabetes, no head-to-head real-world comparisons have evaluated their relative efficacy in preventing dementia.1<\/p>\n \u201cGiven the significant clinical and societal burden of T2DM-related dementia, determining which therapy\u2014 GLP-1 RAs or metformin\u2014provides superior protection against cognitive decline is crucial,\u201d senior author Jiaqiang Zhang, of the department of anesthesiology and perioperative medicine at Zhengzhou University, and colleagues wrote.1 \u201cClarifying this therapeutic distinction will offer crucial guidance for clinicians, policymakers, and researchers, potentially reshaping dementia prevention strategies in T2DM management.\u201d<\/p>\n To assess the comparative effectiveness of GLP-1 RAs and metformin in reducing dementia risk, investigators conducted a retrospective cohort study using data from TriNetX for adults with type 2 diabetes who initiated either GLP-1 RAs or metformin as first-line therapy between November 2004 and November 2024. The index date was defined as the earliest prescription date post-diagnosis, with \u2265 24 months of follow-up required. Investigators employed 1:1 propensity score matching to balance baseline characteristics between patients on GLP-1 RAs and patients on metformin.1<\/p>\n The primary outcome was the incidence of overall dementia, defined as the first occurrence of a diagnosis of vascular dementia, Alzheimer\u2019s disease, unspecified dementia, or dementia associated with other diseases. Secondary outcomes included the incidence of specific dementia subtypes and all-cause mortality.1<\/p>\n To address potential biases from pre-existing or undiagnosed dementia and to allow sufficient time for the therapeutic effects of the medications to manifest, investigators applied a 6-month washout period. Follow-up began on day 181 after the index date and continued until the first occurrence of an outcome, loss to follow-up, or the conclusion of the study period.1<\/p>\n Among 87,229 matched patients per cohort, GLP-1 RA use was associated with a significantly reduced risk of overall dementia (adjusted hazard ratio [aHR], 0.90; 95% CI, 0.85-0.95), Alzheimer\u2019s disease (aHR, 0.88; 95% CI, 0.83-0.94), and non-vascular dementias (aHR, 0.75; 95% CI, 0.70-0.81) compared with metformin. However, no significant difference was observed for vascular dementia. Further analysis revealed the all-cause mortality rate was notably reduced in the GLP-1 RA group (aHR, 0.89; 95% CI, 0.81-0.95).1<\/p>\n Subgroup analyses showed consistent benefit across age and sex. Investigators noted the benefits were most pronounced in patients aged \u226560 years, with significant reductions noted in those 60\u201379 years of age (aHR, 0.85; 95% CI, 0.80-0.90) and \u2265 80 years of age (aHR, 0.80; 95% CI, 0.74-0.88). Additionally, while both sexes benefitted, investigators pointed out females had a slightly lower aHR (0.83; 95% CI, 0.79-0.89) compared with males (0.90; 95% CI, 0.84-0.97).1<\/p>\n \u201cGiven the increasing global burden of diabetes-related cognitive decline and the lack of head-to-head comparisons between GLP-1 RAs and metformin, our findings provide actionable insights for clinical decision-making and may inform future guidelines. Additionally, the study underscores the importance of tailoring therapeutic strategies to optimize both metabolic and neuroprotective outcomes in high-risk T2DM populations,\u201d investigators concluded.1 \u201cFurther randomized controlled trials are warranted to confirm these findings and evaluate the long-term cognitive benefits of GLP-1 RAs.\u201d<\/p>\n ReferencesSun M, Wang X, Lu Z, et al. Evaluating GLP-1 receptor agonists versus metformin as first-line therapy for reducing dementia risk in type 2 diabetes. BMJ Open Diab Res Care 2025;13:e004902. doi:10.1136\/ bmjdrc-2025-004902Alzheimer\u2019s Society. Diabetes and the risk of dementia. August 2024. Accessed July 22, 2025. https:\/\/www.alzheimers.org.uk\/about-dementia\/managing-the-risk-of-dementia\/reduce-your-risk-of-dementia\/diabetes<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may be more effective than metformin for reducing the risk of dementia…\n","protected":false},"author":2,"featured_media":28606,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[12752,64,63,5240,27388,27390,1835,4046,1730,27392,2156,27396,137,500,27397,17974,21962,27394,5296,8122,490,1679,44,27391,4334,19174,13129,13972,27393,27389,2283,337,27395,128,27387],"class_list":["post-28605","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-allergy","tag-au","tag-australia","tag-cardiology","tag-clinicians","tag-dermatology","tag-diabetes","tag-doctors","tag-drugs","tag-endocrinology","tag-fda","tag-gastroenterology","tag-health","tag-healthcare","tag-hematology","tag-infectious-disease","tag-insight","tag-internal-medicine","tag-interviews","tag-medical","tag-medication","tag-medicine","tag-news","tag-ophthalmology","tag-pharmaceuticals","tag-pipeline","tag-primary-care","tag-providers","tag-psychiatry","tag-pulmonology","tag-rare-disease","tag-research","tag-rheumatology","tag-science","tag-treatments"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/28605","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=28605"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/28605\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/28606"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=28605"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=28605"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=28605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}